News

More than 30% of Medicare Part D beneficiaries who receive opioid prescriptions are prescribed them from multiple providers, according to a study published in the British Medical Journal. This practice, which goes against recommended guidelines of a single provider prescribing opioids for a patient, was found to be associated with higher rates of opioid-related hospitalization.

Actavis plans to purchase Forest Laboratories for approximately $25 billion in a cash and equity deal, creating a combination of “two of the world’s fastest growing specialty pharmaceutical companies, with combined annual revenues of more than $15 billion in 2015,” according to a Feb. 18 announcement.

Pharmacy as a profession dropped a few notches to fifth place in the most recent U.S. News & World Report rankings for all jobs and placed third on the list of best healthcare jobs, behind nurse practitioner and dentist. It had placed third as the best profession overall last year.

Boehringer Ingelheim is facing lawsuits in the United States over claims that dabigatran etexilate mesylate (Pradaxa) capsules, a blood-thinner used to reduce the risk of stroke and blood clots in people with atrial fibrillation not caused by a heart valve problem, causes severe and fatal bleeding.

Nearly 12% of Medicare patients who receive inpatient rehabilitation following discharge from acute-care hospitalization are readmitted to the hospital within 30 days after discharge from the rehabilitation facility, according to a study in the Feb. 12 issue of the Journal of the American Medical Association.

Taking low-dose aspirin regularly can reduce the risk of ovarian cancer, according to researchers at the National Cancer Institute. However, more research is needed before any recommendations are instituted.

The National Institutes of Health (NIH), FDA, 10 biopharmaceutical companies, the Pharmaceutical Research and Manufacturers of America, and several nonprofit organizations have launched an unprecedented public/private partnership to “transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of disease,” announced a recent statement from the NIH.